Comparing antibody and small-molecule therapies for cancer (Q34560075)

3 August 2017

1 reference

title

Comparing antibody and small-molecule therapies for cancer (English)

1 reference

3 August 2017

1 reference

Kohzoh Imai

1

1 reference

3 August 2017

Akinori Takaoka

series ordinal

2

1 reference

3 August 2017

language of work or name

English

0 references

publication date

1 September 2006

1 reference

3 August 2017

Nature Reviews Cancer

1 reference

3 August 2017

6

1 reference

3 August 2017

714-727

1 reference

3 August 2017

9

1 reference

https://scigraph.springernature.com/pub.10.1038/nrc1913

3 August 2017

0 references

cites work

Timeline: Chemotherapy and the war on cancer.

1 reference

31 March 2020

Targeted cancer therapy

1 reference

31 March 2020

The Hallmarks of Cancer

1 reference

Targeting tyrosine kinases in cancer: the second wave

31 March 2020

1 reference

Imatinib mesylate--a new oral targeted therapy

31 March 2020

1 reference

Gefitinib--a novel targeted approach to treating cancer

31 March 2020

1 reference

Improving the efficacy of antibody-based cancer therapies

31 March 2020

1 reference

The ErbB signaling network: receptor heterodimerization in development and cancer

31 March 2020

1 reference

Untangling the ErbB signalling network

31 March 2020

1 reference

Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer

31 March 2020

1 reference

Continuous cultures of fused cells secreting antibody of predefined specificity

31 March 2020

1 reference

Antigen-specific human monoclonal antibodies from mice engineered with human Ig heavy and light chain YACs

31 March 2020

1 reference

Humanization of an anti-p185HER2 antibody for human cancer therapy

31 March 2020

1 reference

Protein therapeutics: new applications for pharmacogenetics

31 March 2020

1 reference

Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex

31 March 2020

1 reference

Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer

31 March 2020

1 reference

Establishment and characterization of mouse-human chimeric monoclonal antibody to erbB-2 product

31 March 2020

1 reference

Monoclonal antibodies as effective therapeutic agents for solid tumors

31 March 2020

1 reference

Human tumor growth suppression by apoptosis induced with anti-ErbB-2 chimeric monoclonal antibody.

31 March 2020

1 reference

The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells.

31 March 2020

1 reference

Epidermal growth factor receptor inhibition in cancer therapy: biology, rationale and preliminary clinical results

31 March 2020

1 reference

The EGFR as a target for anticancer therapy--focus on cetuximab

31 March 2020

1 reference

31 March 2020

1 reference

Randomized phase III trial results of panitumumab, a fully human anti-epidermal growth factor receptor monoclonal antibody, in metastatic colorectal cancer

31 March 2020

1 reference

Tumour biology: herceptin acts as an anti-angiogenic cocktail.

31 March 2020

1 reference

Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody

31 March 2020

1 reference

Therapeutic antibodies for human diseases at the dawn of the twenty-first century

31 March 2020

1 reference

31 March 2020

Engineered antibodies

1 reference

Role of tyrosine kinase inhibitors in cancer therapy

31 March 2020

1 reference

Tyrosine kinases as targets for cancer therapy

31 March 2020

1 reference

STI571 (Gleevec) as a paradigm for cancer therapy

31 March 2020

1 reference

Imatinib as a paradigm of targeted therapies

31 March 2020

1 reference

STI571 as a targeted therapy for CML.

31 March 2020

1 reference

Pharmacology of imatinib (STI571).

31 March 2020

1 reference

The epidermal growth factor receptor as a target for cancer therapy

31 March 2020

1 reference

Advances in molecular diagnostics and therapeutics in head and neck cancer

31 March 2020

1 reference

Inhibitors of prenylation of Ras and other G-proteins and their application as therapeutics

31 March 2020

1 reference

Raf kinase as a target for anticancer therapeutics

31 March 2020

1 reference

Heat-shock protein 90 inhibitors as novel cancer chemotherapeutics - an update

31 March 2020

1 reference

Cancer metastasis therapeutic targets and drug discovery: emerging small-molecule protein kinase inhibitors

31 March 2020

1 reference

Matrix metalloproteinase inhibitors as anticancer therapeutics.

31 March 2020

1 reference

Cancer. Encouraging results for second-generation antiangiogenesis drugs

31 March 2020

1 reference

Upping the ante on antibodies.

31 March 2020

1 reference

Monoclonal antibody successes in the clinic

31 March 2020

1 reference

Can the pharmaceutical industry reduce attrition rates?

31 March 2020

1 reference

Small molecule and monoclonal antibody therapies in neurooncology

31 March 2020

1 reference

Issues and progress with protein kinase inhibitors for cancer treatment

31 March 2020

1 reference

Potent antibody therapeutics by design

31 March 2020

1 reference

Structural basis for inhibition of the epidermal growth factor receptor by cetuximab

31 March 2020

1 reference

Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab

31 March 2020

1 reference

Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.

31 March 2020

1 reference

Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells

31 March 2020

1 reference

Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.

31 March 2020

1 reference

Pharmacokinetic and pharmacodynamic properties of EGFR inhibitors under clinical investigation.

31 March 2020

1 reference

Epidermal growth factor receptor tyrosine kinase inhibitors

31 March 2020

1 reference

Erlotinib in previously treated non-small-cell lung cancer

31 March 2020

1 reference

Intrinsic and acquired resistance to EGFR inhibitors in human cancer therapy.

31 March 2020

1 reference

Differential sensitivity of cancer cells to inhibitors of the epidermal growth factor receptor family.

31 March 2020

1 reference

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

31 March 2020

1 reference

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

31 March 2020

1 reference

Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib

31 March 2020

1 reference

High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan

31 March 2020

1 reference

Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications.

31 March 2020

1 reference

Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer.

31 March 2020

1 reference

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

31 March 2020

1 reference

Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers

31 March 2020

1 reference

Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255.

31 March 2020

1 reference

Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer

31 March 2020

1 reference

Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients

31 March 2020

1 reference

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib

31 March 2020

1 reference

Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.

31 March 2020

1 reference

Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations

31 March 2020

1 reference

Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry.

31 March 2020

1 reference

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

31 March 2020

1 reference

A phase II trial of ZD1839 (Iressa) 750 mg per day, an oral epidermal growth factor receptor-tyrosine kinase inhibitor, in patients with metastatic colorectal cancer

31 March 2020

1 reference

Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

31 March 2020

1 reference

Molecular alterations in tumors and response to combination chemotherapy with gefitinib for advanced colorectal cancer

31 March 2020

1 reference

Targeting the epidermal growth factor receptor in colorectal cancer: advances and controversies

31 March 2020

1 reference

Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study

31 March 2020

1 reference

Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors

31 March 2020

1 reference

Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways

31 March 2020

1 reference

Stem cells, cancer, and cancer stem cells

31 March 2020

1 reference

Tumour stem cells and drug resistance

31 March 2020

1 reference

Dynamics of chronic myeloid leukaemia.

31 March 2020

1 reference

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

31 March 2020

1 reference

Role of antibody-dependent cell-mediated cytotoxicity in the efficacy of therapeutic anti-cancer monoclonal antibodies.

31 March 2020

1 reference

Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene

31 March 2020

1 reference

Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma

31 March 2020

1 reference

Expression of complement inhibitors CD46, CD55, and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma

31 March 2020

1 reference

In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas.

31 March 2020

1 reference

Complement activation determines the therapeutic activity of rituximab in vivo.

31 March 2020

1 reference

Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents

31 March 2020

1 reference

Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts

31 March 2020

1 reference

Immune evasion of tumor cells using membrane-bound complement regulatory proteins

31 March 2020

1 reference

Engineered antibody Fc variants with enhanced effector function

31 March 2020

1 reference

Optimization of humanized IgGs in glycoengineered Pichia pastoris.

31 March 2020

1 reference

Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity

31 March 2020

1 reference

Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas

31 March 2020

1 reference

Engineered antibodies with increased activity to recruit complement

31 March 2020

1 reference

Targeting epidermal growth factor receptor--are we missing the mark?

31 March 2020

1 reference

Dermatologic Side Effects Associated with Gefitinib Therapy: Clinical Experience and Management

31 March 2020

1 reference

Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining?

31 March 2020

1 reference

Medical treatment of non-small-cell lung cancer

31 March 2020

1 reference

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

31 March 2020

1 reference

Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin.

31 March 2020

1 reference

Severe acute interstitial pneumonia and gefitinib

31 March 2020

1 reference

Imaging of gefitinib-related interstitial lung disease: multi-institutional analysis by the West Japan Thoracic Oncology Group

31 March 2020

1 reference

Ethnic differences in response to epidermal growth factor receptor tyrosine kinase inhibitors

31 March 2020

1 reference

Multidrug transporter ABCG2 prevents tumor cell death induced by the epidermal growth factor receptor inhibitor Iressa (ZD1839, Gefitinib).

31 March 2020

1 reference

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

31 March 2020

1 reference

Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer

31 March 2020

1 reference

Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.

31 March 2020

1 reference

Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.

31 March 2020

1 reference

Multicenter phase I/II study of cetuximab with paclitaxel and carboplatin in untreated patients with stage IV non-small-cell lung cancer

31 March 2020

1 reference

Cetuximab: an epidermal growth factor receptor monoclonal antibody for the treatment of colorectal cancer

31 March 2020

1 reference

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

31 March 2020

1 reference

p53-dependent apoptosis modulates the cytotoxicity of anticancer agents

31 March 2020

1 reference

Integration of interferon-alpha/beta signalling to p53 responses in tumour suppression and antiviral defence.

31 March 2020

1 reference

EGFR blockade by cetuximab alone or as combination therapy for growth control of hepatocellular cancer

31 March 2020

1 reference

Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab

31 March 2020

1 reference

Gefitinib versus cetuximab in lung cancer: round one.

31 March 2020

1 reference

Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016.

31 March 2020

1 reference

Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells

31 March 2020

1 reference

31 March 2020

1 reference

A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling

31 March 2020

1 reference

Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells

31 March 2020

1 reference

PTEN maintains haematopoietic stem cells and acts in lineage choice and leukaemia prevention

31 March 2020

1 reference

A small molecule-kinase interaction map for clinical kinase inhibitors

31 March 2020

1 reference

Current status of small-molecule tyrosine kinase inhibitors targeting epidermal growth factor receptor in colorectal cancer

31 March 2020

1 reference

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/NRC1913

1 reference

Dimensions Publication ID

3 August 2017

0 references

1 reference